AVX-470, an orally-delivered GI-targeted anti-TNF bio-better
blockbuster anti-TNF monoclonal antibodies are currently on the market to treat Ulcerative colitis and CrohnâÂ?Â?s disease. Discussion will center on the manufacturing of AVX-470, AvaxiaâÂ
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
blockbuster anti-TNF monoclonal antibodies are currently on the market to treat Ulcerative colitis and CrohnâÂ?Â?s disease. Discussion will center on the manufacturing of AVX-470, AvaxiaâÂ
unique names. Case in point: A poster presentation at the European Crohn’s and Colitis Organization titled “Biosimilar but not the same” offered timely and real-world data
compound containing both molecules, aimed as an improved treatment of ulcerative colitis. The present case investigated the capacity of the two active agents to interact and generate
Chronic ulcerative colitis (UC) leads to increased risk of colorectal cancer. Dextran sulfate sodium (DSS) administration to mice is a widely used model for UC and UC-associated neoplasia; however
adapter molecule ASC. We previously demonstrated that the NLRP3 inflammasome protects mice from experimental colitis and colorectal tumorigenesis. The NLRP3 inflammasome-dependent protection of intestinal inflammation…
Clostridium difficile is the major cause of hospital-acquired infectious diarrhea and colitis in developed countries. The pathogenicity of C. difficile is mainly mediated by the release of two potent
Chronic ulcerative colitis (UC) leads to increased risk of colorectal cancer. Dextran sulfate sodium (DSS) administration to mice is a widely used model for UC and UC-associated neoplasia, however
Inflammatory bowel disease, mainly CrohnâÂ?Â?s disease and ulcerative colitis, still draw great attention to the researchers and still challenge the gastroenterologists in their clinical daily practice mainly
treatment of mice did not induce toxicity. In the chronic DSS-induced model of colitis, as well as in the adoptive T cell transfer model, intestinal fibrosis develops only marginally
treatment in inflammatory bowel disease (IBD) namely CrohnâÂ?Â?s disease (CD) and ulcerative colitis (UC). However, this treatment is associated with high costs and the possibility of severe adverse
enterica, a new Bradyrhizobium species recently identified in biopsies of patients with the cord colitis syndrome using HTS; do not carry nitrogen fixation and nodulation genes commonly found in symbiotic
compound containing both molecules, aimed as an improved treatment of ulcerative colitis. The present case investigated the capacity of the two active agents to interact and generate
conducted. Among 13 reviewed cases (12 of Crohn’s disease and one of ulcerative colitis), AG was diagnosed between the ages of 26 and 58 years. Among these cases, thyroid
ammatory conditions of the gastrointestinal tract and comprise Crohn’s disease (CD) and ulcerative colitis (UC). Both CD and UC are characterized by a great extent of heterogeneity, in terms
carriers of MDR1 C3435T polymorphism are speculated to have an increased susceptibility to ulcerative colitis (UC) in western countries. The aim of this study is to investigate whether MDR1 C3435T
effective in the management of HIV enteropathy, diarrhea predominant irritable bowel syndrome, ulcerative colitis, Crohn’s Disease, pouchitis and C. difficle colitis. Data will be presented of clinical outcomes from
have been used to segregate patients by disease activity and, in the case of colitis, the type of disease. The correlation of VOMs with microbiota is interesting and supports
processes in IBD using samples of Portuguese patients with Crohn’s Disease and Ulcerative Colitis. Our findings have demonstrated that experiential avoidance, i.e. one’s unavailability to accept internal events
Inflammatory bowel diseases (IBD), including Crohn\\\\\\\\\\\\\\'s disease and ulcerative colitis, are chronic inflammatory diseases with a significant increase in cases in recent years. The exact etiology of IBD remains
established treatment in inflammatory bowel disease (IBD) namely Crohn’s disease (CD) and ulcerative colitis (UC). However, this treatment is associated with high costs and the possibility of severe adverse
treatment of mice did not induce toxicity. In the chronic DSS-induced model of colitis, as well as in the adoptive T cell transfer model, intestinal fibrosis develops only marginally
world population has latent TB infection. Patients with Crohn\\'s disease and Ulcerative Colitis that are treated with anti TNF-alfa agents, have a 14 times higher risk of reactivation
compare safety profile of therapy in patients with ulcerative colitis (UC) and Crohn disease (СD), receiving anti-inflammatory therapy, using bone marrow-derived mesenchymal stromal cells (MSC) and standard therapy
records of pediatric patients started on 6-MP for Crohnâ??s ileitis and/or colitis was performed. The Pediatric Crohnâ??s Disease Activity Index (PCDAI) score and Simple Endoscopic Score
For authors and organisers
Find the right journal for your paper and submit your manuscript.